- Home
- STOK vs BCRX Comparison
STOK vs BCRX Comparison
Compare STOK & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STOK
- BCRX
- Stock Information
- Founded
- STOK 2014
- BCRX 1986
- Country
- STOK United States
- BCRX United States
- Employees
- STOK N/A
- BCRX N/A
- Industry
- STOK Biotechnology: Pharmaceutical Preparations
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STOK Health Care
- BCRX Health Care
- Exchange
- STOK Nasdaq
- BCRX Nasdaq
- Market Cap
- STOK 1.3B
- BCRX 1.4B
- IPO Year
- STOK 2019
- BCRX 1994
- Fundamental
- Price
- STOK $31.97
- BCRX $7.21
- Analyst Decision
- STOK Strong Buy
- BCRX Strong Buy
- Analyst Count
- STOK 7
- BCRX 11
- Target Price
- STOK $30.83
- BCRX $19.55
- AVG Volume (30 Days)
- STOK 1.5M
- BCRX 6.8M
- Earning Date
- STOK 11-12-2025
- BCRX 11-03-2025
- Dividend Yield
- STOK N/A
- BCRX N/A
- EPS Growth
- STOK N/A
- BCRX N/A
- EPS
- STOK 0.91
- BCRX N/A
- Revenue
- STOK $199,893,000.00
- BCRX $557,506,000.00
- Revenue This Year
- STOK $416.54
- BCRX $41.40
- Revenue Next Year
- STOK N/A
- BCRX $5.33
- P/E Ratio
- STOK $35.55
- BCRX N/A
- Revenue Growth
- STOK 1218.82
- BCRX 45.85
- 52 Week Low
- STOK $5.35
- BCRX $6.00
- 52 Week High
- STOK $38.69
- BCRX $11.31
- Technical
- Relative Strength Index (RSI)
- STOK 62.96
- BCRX 47.92
- Support Level
- STOK $31.19
- BCRX $6.44
- Resistance Level
- STOK $34.86
- BCRX $6.92
- Average True Range (ATR)
- STOK 2.77
- BCRX 0.31
- MACD
- STOK -0.28
- BCRX 0.07
- Stochastic Oscillator
- STOK 46.19
- BCRX 88.43
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.